{"organizations": [], "uuid": "3842060cb64d3db2dcb2f6dc76f3ecfa272c453d", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180129.html", "section_title": "Archive News &amp; Video for Monday, 29 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-novo-nordisk-says-does-not-intend/brief-novo-nordisk-says-does-not-intend-to-make-a-revised-proposal-for-ablynx-idUSC7N1JW009", "country": "US", "domain_rank": 408, "title": "BRIEF-Novo Nordisk Says Does Not Intend To Make A Revised Proposal For Ablynx", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.003, "site_type": "news", "published": "2018-01-29T18:11:00.000+02:00", "replies_count": 0, "uuid": "3842060cb64d3db2dcb2f6dc76f3ecfa272c453d"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-novo-nordisk-says-does-not-intend/brief-novo-nordisk-says-does-not-intend-to-make-a-revised-proposal-for-ablynx-idUSC7N1JW009", "ord_in_thread": 0, "title": "BRIEF-Novo Nordisk Says Does Not Intend To Make A Revised Proposal For Ablynx", "locations": [], "entities": {"persons": [{"name": "stine jacobsen", "sentiment": "none"}], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "brief-novo nordisk", "sentiment": "negative"}, {"name": "novo nordisk", "sentiment": "negative"}, {"name": "ablynx", "sentiment": "none"}, {"name": "sanofi", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 29 (Reuters) - NOVO NORDISK A/S:\n* NOVO NORDISK SAYS DOES NOT INTEND TO MAKE A REVISED PROPOSAL FOR ABLYNX\n* NOVO NORDISK SAYS LOOKS FORWARD TO CONTINUE ITS PRODUCTIVE RESEARCH COLLABORATION WITH ABLYNX\n* FRENCH DRUGMAKER SANOFI SAID ON MONDAY IT HAS AGREED TO BUY THE BELGIAN BIOTECH COMPANY FOR 3.9 BILLION EUROS ($4.8 BILLION) FURTHER COMPANY COVERAGE: (Reporting by Stine Jacobsen)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-29T18:11:00.000+02:00", "crawled": "2018-01-30T19:03:37.000+02:00", "highlightTitle": ""}